Dear Editor:

Hereditary epidermolysis bullosa (HEB) constitutes a diverse group of genodermatoses characterized by trauma-induced skin fragility, blisters and erosions. The fragility of the skin and mucous membranes results from abnormalities in the cytoskeleton of the basal keratinocytes or of the basement membrane zone[@B1]. Faced to the great heterogeneity of this disease, long and/or numerous exons of HEB genes, it was necessary to use next generation sequencing techniques, as an approach for disease-gene and variant causing identification[@B2]. In this study, we carried out whole exome sequencing (WES) analysis in one Libyan patient in order to identify the molecular aetiology of HEB.

The patient is the first child of a consanguineous healthy couple without a HEB familial history, originating from Libya. The baby was born without apparent abnormalities. After three days of birth, blisters followed by erosions and ulceration of skin sites prone to friction appeared. The mucous membranes were affected. Nail dystrophy was also observed. This study was conducted according to the declaration of Helsinki and to the ethical standards of the authors Institutional Review Board (Registration number IRB00005445, FWA00010074). After signing an informed consent, blood samples were collected and genomic DNA was isolated. WES was carried out using 5 µg of the genomic DNA sample.

Classical investigation of HEB is generally performed by electronic microscopy or/and immunofluorescence followed by mutational screening. However, this approach is expensive and time-consuming mainly in laboratories lacking logistics and human resources. Large genes like *COL7A1* and *PLEC1* and the presence of pseudogenes for *KRT14* represent a major difficulty to perform molecular diagnosis. Direct sequencing of all *COL7A1* coding regions might be challenging as they encompass 118 exons, and more than 70 polymerase chain reaction primer pairs are necessary for the amplification of all coding regions[@B3]. In addition, the genetic heterogeneity and the important number of "private mutation" make the genetic diagnosis more challenging even in endogamous populations[@B4]. WES has led to the identification of a considerable number of pathogenic mutations in monogenic Mendelian disorders, including skin pathologies[@B5]. Indeed, in comparison to individual genes such as *COL7A1*, Sanger sequencing costs are similar to the entire cost of WES[@B3].

The library preparation, capture, sequencing, variant detection and annotation were performed by Oxford Gene Technology (OGT), (London, UK). Filtering steps were initiated by excluding reads with a coverage \<20 and polymorphisms with a frequency \>1%, according to OGT data, and polymorphisms for each gene involved in HEB were extracted ([Table 1](#T1){ref-type="table"}). Finally, all the variants reported in the Exome Variant Server and Exome Aggregation Consortium databases were excluded. These analyzes allowed the identification of a novel homozygous variant (c.2701+1G\>A) occurring at the 18th donor splice site of LAMB3 gene in the affected sibling, and at the heterozygous state in the clinically unaffected parents. The c.2701+1G\>A has been confirmed by Sanger sequencing of the corresponding DNA fragment. This variant was not present in 44 ethnically matched unrelated controls (88 chromosomes).

Splicing abnormalities are common in human diseases. These mutations can result in either complete skipping of one or more exons, retention of an intron or the introduction of a new splice site within an exon or an intron[@B6]. The most deleterious single nucleotide substitutions in donor or acceptor splice sites involve the +1/+2 or −1/−2 positions[@B7]. For our patient, the G to T transition at +1 bp position downstream exon 18 is predicted to abolish the 18th donor splice site according to Berkeley Drosophila Genome Project (<http://www.fruitfly.org/seq_tools/splice.html>). Thus, the affected splice site would lead to an aberrant transcript with an in-frame skipping of the last 82 nucleotides of exon 18. This aberrant splicing is predicted to result in a truncated β3 chain of laminin 332 with a loss of 25% (299 carboxyl-terminal amino acids) of the β3 chain due to a frame shift and a premature termination at codon 904. The predicted β3 chain mutant has 873 amino acids that are identical to the normal β3 chain while the last 31 amino acids are different ([Fig. 1](#F1){ref-type="fig"}). The creation of a premature stop codon could result in the degradation of the *LAMB3* mRNA by the nonsense-mediated decay mechanism.

The severity of the disease depends on the nature, the location and the impact of the mutation at transcriptional and translational levels. Mutations affecting the short arm of β3 chain of laminin 332 have been reported to be responsible of the Herlitz JEB (H-JEB) phenotype[@B8]. The H-JEB is characterized by profound skin fragility and mucocutaneous blistering with loss of fluids and proteins, making affected infants susceptible to infections. The long-term consequences include failure to thrive, anaemia, dyspnoea, pneumonia or sepsis, which explain the high mortality observed within the two first years of life[@B9].

For these reasons and to avoid having other children with JEB, the family has requested a molecular diagnosis. By identifying the molecular aetiology of the disease, prenatal diagnosis has been planned to give parents the chance of having an unaffected child.

In this paper, we report on the molecular study of a Libyan patient with HEB. This is to our knowledge the first study of a Libyan patient. Our previous studies showed that despite mutational heterogeneity of HEB, some mutations are likely founder and closed to specific geographic regions[@B4]. Therefore, screening of c.2701+1G\>A mutation could assist in determining the molecular aetiology of HEB among eastern Libyan patients.

Taken together, our results demonstrate that whole-exome sequencing could be used as a reliable and time-efficient technique for molecular aetiology determination, especially for heterogeneous disorders like HEB, particularly in unexplored areas.
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###### Variants identified after the first filter step (coverage of reads \>20, MAF \<1%)

![](ad-29-243-i001)

  Gene          Polymorphism                     Chromosomal position   Homozygous/Heterozygous   Type of polymorphism   Localisation    MAF (%)   Prediction               
  ------------- -------------------------------- ---------------------- ------------------------- ---------------------- --------------- --------- ------------ ----------- ---------
  *COL7A1*      rs35018203                       3:48602523             Homozygous                Deletion               Intron          99.9984   0            Unknown     Unknown
  rs66737445    3:48605076                       Heterozygous           Deletion                  Splice region          0               4.212     NM           NM          
  rs201839881   3:48605573                       Heterozygous           Non synonymous coding     Exon                   0               0         Unknown      Tolerated   
  NR            3:48621834                       Heterozygous           Substitution              Intron                 0               0.01633   \-                       
  *FERMT1*      No variant found for this gene                                                                                                                              
  *DSP*         rs2806234                        6:7563983              Homozygous                Synonymous coding      Exon            99.9985   99.91        Unknown     Unknown
  *DST*         No variant found for this gene                                                                                                                              
  *KRT5*        No variant found for this gene                                                                                                                              
  *KRT14*       No variant found for this gene                                                                                                                              
  *PLEC*        No variant found for this gene                                                                                                                              
  *PKP1*        rs1722759                        1:201288898            Homozygous                Substitution           Intron          99.875    99.62        NM          NM
  *COL17A1*     NR                               10:105819535           Heterozygous              Substitution           Intron          0         0            NM          NM
  *ITGA6*       No variant found for this gene                                                                                                                              
  *ITGB4*       rs34275940                       17:73723454            Homozygous                Deletion               Intron          99.999    100          NM          NM
  *LAMA3*       rs112340800                      18:21293870            Heterozygous              Deletion               Intron          77.8241   \-           NM          NM
  rs1154233     18:21511089                      Homozygous             Non synonymous coding     Exon                   0               100       Beningn      Tolerated   
  *LAMC2*       No variant found for this gene                                                                                                                              
  *LAMB3*       NR                               1:209795880            Homozygous                Substitution           Splice region   0         0            NM          NM

MAF: minor allele frequency, EVS: Exome Variant Server, ExAc: Exome Aggregation Consortium, NM: not mentioned, NR: not reported.
